相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cardiovascular Outcomes With the Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes and Chronic Kidney Disease An Updated Meta-Analysis of Randomized Controlled Trials
Aaqib H. Malik et al.
CARDIOLOGY IN REVIEW (2020)
Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial
Hiddo J. L. Heerspink et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2020)
Risk of amputation associated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of five randomized controlled trials
Satoshi Miyashita et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2020)
Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes
Mark C. Petrie et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Acute kidney injury with sodium-glucose co-transporter-2 inhibitors: A meta-analysis of cardiovascular outcome trials
Richard E. Gilbert et al.
DIABETES OBESITY & METABOLISM (2019)
Effects of SGLT2 inhibitors on fractures and bone mineral density in type 2 diabetes: An updated meta-analysis
Xiaoyu Li et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2019)
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
V. Perkovic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Possible Mechanism of Hematocrit Elevation by Sodium Glucose Cotransporter 2 Inhibitors and Associated Beneficial Renal and Cardiovascular Effects
Motoaki Sano et al.
CIRCULATION (2019)
Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups Results From the Randomized CREDENCE Trial
Kenneth W. Mahaffey et al.
CIRCULATION (2019)
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
J. J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Thomas A. Zelniker et al.
LANCET (2019)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
S. D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Sodium-glucose Cotransporter 2 Inhibitors in Heart Failure: Potential Mechanisms of Action, Adverse Effects and Future Developments
Juan Tamargo
EUROPEAN CARDIOLOGY REVIEW (2019)
SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials
Robert Puckrin et al.
ACTA DIABETOLOGICA (2018)
Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function: Data From the CANVAS Program
Brendon L. Neuen et al.
CIRCULATION (2018)
Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program
Karin Radholm et al.
CIRCULATION (2018)
SGLT2 inhibition and kidney protection
Josselin Nespoux et al.
CLINICAL SCIENCE (2018)
SGLT2 inhibition and heart failure-current concepts
Joaquim Silva Custodio et al.
HEART FAILURE REVIEWS (2018)
Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis
Muhammad Shariq Usman et al.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2018)
Cardiovascular Safety, Long-Term Noncardiovascular Safety, and Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Systemic Review and Meta-Analysis With Trial Sequential Analysis
Xin-Lin Zhang et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2018)
Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease
Christoph Wanner et al.
CIRCULATION (2018)
How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial
Silvio E. Inzucchi et al.
DIABETES CARE (2018)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Sodium-glucose cotransporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: A meta-analysis
Darin Ruanpeng et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2017)
Effects of SGLT-2 inhibitors on diabetic ketoacidosis: A meta-analysis of randomised controlled trials
Matteo Monami et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2017)
CV Protection in the EMPA-REG OUTCOME Trial: A Thrifty Substrate Hypothesis
Ele Ferrannini et al.
DIABETES CARE (2016)
Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial
David Fitchett et al.
EUROPEAN HEART JOURNAL (2016)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
David Z. I. Cherney et al.
CIRCULATION (2014)
Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
H. J. Lambers Heerspink et al.
DIABETES OBESITY & METABOLISM (2013)
分享论文
